Oral Rifamycin SV Compositions
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/IB2018/058748, filed Nov 7, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,036,316 | Oral Rifamycin SV Compositions In force · High confidence | Cosmo Technologies Ltd. | In force | High confidence | ||
| US 11,564,883 | Oral Rifamycin SV Compositions In force · High confidence | Cosmo Technologies Ltd. | In force | High confidence | ||
| Application 18/678,539 | Oral Rifamycin SV Compositions Pending Not granted | Cosmo Technologies Ltd. | Pending | Not granted |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Cosmo Technologies Limited.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.